UBC29 Antibody

What is UBC9 and What is its Biological Significance in Research?

UBC9, also known as UBE2I or UBCE9, is a critical member of the ubiquitin-conjugating enzyme family. It functions as a homologue of the E2 ubiquitin conjugating enzyme and plays an essential role in the SUMOylation pathway by facilitating the covalent attachment of SUMO-1 molecules to target proteins . The 18 kDa protein (observed at approximately 21 kDa in some experimental conditions) is encoded by gene ID 7329 and has become a significant focus in research due to its involvement in numerous cellular processes including nuclear transport, transcriptional regulation, and maintenance of genome integrity .

UBC9's tissue distribution pattern shows high expression levels in spleen and lung tissues, moderate expression in kidney and liver, and lower amounts in brain . Interestingly, the standard 18 kDa band of UBC9 is frequently barely detectable or absent in heart and skeletal muscle tissues, which presents unique considerations for experimental design when working with these specific tissue types .

Selection Guidelines Based on Application Types

Selection of the appropriate UBC9 antibody depends critically on your experimental application and the specific epitopes you need to target. For instance, catalog number 14837-1-AP (UBE2I-Specific antibody) has been validated for Western Blot (WB), Immunoprecipitation (IP), Immunofluorescence (IF), Immunohistochemistry (IHC), and ELISA applications . Similarly, 10224-1-AP targets UBC9 in WB, IHC, and ELISA applications .

The following table summarizes recommended dilutions for different applications:

For optimal results, antibody dilutions should be titrated for each specific experimental system . Additionally, researchers should cross-reference publications that have successfully used these antibodies for similar applications to inform their experimental design.

What are the Critical Methodological Considerations for Successful UBC9 Detection in Western Blotting?

Western blot detection of UBC9 requires careful attention to protein extraction methods, loading controls, and potential cross-reactivity. Based on technical specifications, researchers should note that UBC9 antibodies detect the protein at either 18 kDa (calculated molecular weight) or 21 kDa (observed molecular weight depending on the antibody used) .

For optimal protein extraction, use buffers containing protease inhibitors to prevent degradation of UBC9. When working with tissues known to have variable UBC9 expression, such as heart and skeletal muscle, additional optimization may be necessary as standard detection methods might yield minimal signal.

For immunohistochemistry applications, antigen retrieval should be performed using TE buffer at pH 9.0, although citrate buffer at pH 6.0 can serve as an alternative . This methodology significantly affects epitope accessibility and staining quality.

Sample preparation is critical when working with UBC9. Complete lysis of nuclear components is essential as UBC9 has significant nuclear localization. Researchers should consider using specialized nuclear extraction protocols when quantitative assessment of UBC9 levels is required.

Multi-level Validation Approach

Establishing antibody specificity is crucial for experimental rigor. A comprehensive validation approach for UBC9 antibodies should include:

• Knockout/knockdown controls: Comparing signal between wild-type samples and those with UBC9 knockdown or knockout can confirm specificity.

• Multiple antibody verification: Using different antibodies targeting distinct epitopes of UBC9 (such as 14837-1-AP and 10224-1-AP) can provide cross-validation .

• Peptide competition assays: Pre-incubating the antibody with excess immunogen peptide should abolish specific binding if the antibody is truly specific.

• Cross-species reactivity testing: Both 14837-1-AP and 10224-1-AP demonstrate reactivity with human, mouse, and rat samples, allowing for cross-species verification of specificity .

• Technical controls: Including positive controls from tissues known to express high levels of UBC9 (spleen, lung) alongside low-expression tissues as negative controls (heart, skeletal muscle) .

An important consideration is that some antibodies may detect additional bands beyond the expected molecular weight, which may represent post-translationally modified forms of UBC9 rather than non-specific binding.

Integrated Methodological Framework

Studying UBC9-mediated SUMOylation requires a multifaceted approach combining UBC9 antibodies with additional techniques:

• Co-immunoprecipitation with UBC9 antibodies: This enables identification of proteins interacting with UBC9 during the SUMOylation process. Both catalog numbers 14837-1-AP and 10224-1-AP can be optimized for immunoprecipitation applications, though specific validation may be required .

• Sequential immunoprecipitation: First pulling down with SUMO antibodies followed by Western blotting with target protein antibodies (or vice versa) can identify SUMOylated proteins in specific pathways.

• Proximity ligation assays: Combining UBC9 antibodies with antibodies against potential substrate proteins allows visualization of protein interactions in situ with higher sensitivity than conventional co-localization studies.

• SUMOylation site mapping: After identifying UBC9 substrates through antibody-based approaches, mass spectrometry can be employed to precisely map SUMOylation sites.

• In vitro SUMOylation assays: Combining recombinant UBC9 with potential substrates and detecting using UBC9 antibodies can validate direct SUMOylation.

This integrated approach provides a comprehensive understanding of both the substrates and mechanisms of UBC9-mediated SUMOylation in various cellular contexts.

How Does UBC9 Expression Pattern Vary Across Tissues and What Methodological Approaches Best Capture This Variation?

UBC9 exhibits a distinctive tissue-specific expression pattern that requires tailored methodological approaches for accurate detection. Based on research findings, UBC9 is present at high levels in spleen and lung tissues, moderate levels in kidney and liver, and low amounts in brain . The 18 kDa band of UBC9 is barely visible or absent in heart and skeletal muscle extracts using standard techniques .

For accurate assessment of tissue-specific expression patterns, researchers should consider:

• Tissue-specific extraction protocols: Nuclear extraction efficiency varies among tissues and affects UBC9 detection.

• Loading control selection: Traditional housekeeping genes may not normalize equally across tissues; multiple loading controls are recommended.

• Detection method sensitivity: For tissues with low expression (brain, heart, skeletal muscle), enhanced chemiluminescence or fluorescent secondary antibodies may improve detection sensitivity.

• Antibody selection by tissue type: Different UBC9 antibodies may perform differently depending on tissue-specific post-translational modifications or protein complexes.

When comparing UBC9 expression across tissues, standardized protocols for tissue collection, storage, and processing are essential to minimize technical variability that might be misinterpreted as biological differences.

Optimization Framework for Subcellular Localization Studies

When using UBC9 antibodies for immunofluorescence and confocal microscopy, several methodological considerations are critical:

• Fixation method optimization: Paraformaldehyde (4%) is generally suitable, but methanol fixation may better preserve certain epitopes. Test both methods with your specific UBC9 antibody.

• Permeabilization protocol: Since UBC9 has significant nuclear localization, adequate permeabilization (0.1-0.5% Triton X-100) is essential for antibody access to nuclear epitopes.

• Antibody dilution optimization: For UBC9 antibodies, starting with the manufacturer's recommended immunohistochemistry dilutions (1:250-1:1000 for 14837-1-AP; 1:20-1:200 for 10224-1-AP) and further titrating for immunofluorescence is advisable .

• Blocking conditions: Extended blocking (>1 hour) with 5-10% normal serum from the species of the secondary antibody helps reduce background.

• Co-localization controls: When performing co-localization studies between UBC9 and potential substrates, include controls for antibody cross-reactivity and spectral overlap.

• Signal amplification: For tissues with low UBC9 expression, tyramide signal amplification may enhance detection sensitivity while maintaining specificity.

For accurate interpretation of subcellular localization, z-stack imaging with appropriate nuclear counterstains is recommended to distinguish nuclear from perinuclear localization of UBC9.

Systematic Troubleshooting Approach

When faced with contradictory results using different UBC9 antibodies, researchers should implement a systematic approach:

• Epitope mapping comparison: Different antibodies like 14837-1-AP (against a peptide immunogen) and 10224-1-AP (against UBC9 fusion protein) recognize distinct epitopes, which may be differentially accessible in various experimental conditions .

• Validation in knockout/knockdown models: Testing both antibodies in parallel in systems with confirmed UBC9 depletion provides definitive evidence of specificity.

• Post-translational modification interference: Some antibodies may fail to recognize UBC9 when specific residues are phosphorylated or otherwise modified. Treating samples with phosphatases or other enzymes may resolve such discrepancies.

• Protocol standardization: When comparing antibodies, identical protocols for sample preparation, antibody incubation, and detection systems should be used to eliminate technical variables.

• Cross-validation with non-antibody methods: Confirming key findings with techniques like mass spectrometry or RNA expression analysis provides antibody-independent verification.

• Isoform specificity assessment: Verify whether discrepancies might result from differential recognition of UBC9 isoforms or splice variants.

When publishing results, transparent reporting of all validation steps and potential limitations of the antibodies used enhances reproducibility and data interpretation.

Integrated Multi-technique Approach

UBC9 antibodies can be integrated with advanced techniques to comprehensively characterize protein-protein interactions:

• Proximity-dependent biotin identification (BioID): Fusing UBC9 to a biotin ligase allows biotinylation of proximal proteins, which can then be isolated and identified using UBC9 antibodies for verification.

• FRET/BRET analysis: Combining fluorescent/bioluminescent tagging with antibody verification can provide real-time dynamics of UBC9 interactions in living cells.

• Crosslinking mass spectrometry: Chemical crosslinking of interacting proteins followed by immunoprecipitation with UBC9 antibodies and mass spectrometry analysis reveals direct binding partners.

• ChIP-Seq with UBC9 antibodies: Chromatin immunoprecipitation followed by sequencing identifies genomic regions where UBC9 is recruited, potentially through protein-protein interactions with transcription factors.

• Single-molecule imaging: Combining UBC9 antibodies with super-resolution microscopy techniques allows visualization of individual interaction events at nanometer resolution.

Disease-specific Experimental Design Framework

When investigating UBC9's role in disease models, researchers should consider:

• Patient-derived samples: Compare UBC9 expression and SUMOylation patterns between patient and control samples using validated antibodies with established specificity. For immunohistochemistry applications, antibodies 14837-1-AP (1:250-1:1000) and 10224-1-AP (1:20-1:200) have been validated for human tissues .

• Disease-relevant cell types: Focus on cells where UBC9 expression is physiologically relevant, such as lung cancer cells, which have been validated for UBC9 antibody applications .

• Physiological stimulus testing: Examine how disease-relevant stimuli affect UBC9 expression and activity, using antibodies to track changes in protein levels and localization.

• Genetic manipulation models: Create cell or animal models with UBC9 mutations identified in disease states, then use antibodies to study consequent changes in protein interaction networks.

• Therapeutic intervention assessment: Use UBC9 antibodies to evaluate how potential therapeutic compounds affect SUMOylation processes in disease models.

• Time-course experiments: Apply UBC9 antibodies in longitudinal studies to track changes in expression and localization during disease progression or treatment response.

When designing such experiments, researchers should account for the tissue-specific expression patterns of UBC9, particularly its high expression in spleen and lung, moderate levels in kidney and liver, and lower amounts in brain tissue .